Cancer Journal AntiCancer Research: Results with Goleic in one of the clinics: 

Oleic Acid, Deglycosylated Vitamin D-Binding Protein, Nitric Oxide: A Molecular Triad Made Lethal to Cancer

Abstract. Background: Oleic Acid (OA) has been shown to have anticancer properties mediated by interaction with proteins such as α-lactalbumin and lactoferrins. Therefore, we synthesized complexes of OA and Gc protein-derived macrophage activating factor (GcMAF) that inhibits per se cancer cell proliferation and metastatic potential. We hypothesised that OA-GcMAF complexes could exploit the anticancer properties of both OA and GcMAF in a synergistic manner. We postulated that the stimulating effects of GcMAF on macrophages might lead to release of nitric oxide (NO). Patients and Methods: Patients with advanced cancer were treated at the Immuno Biotech Treatment Centre with OA- GcMAF-based integrative immunotherapy in combination with a low-carbohydrate, high-protein diet, fermented milk products containing naturally-produced GcMAF, Vitamin D3, omega-3 fatty acids and low-dose acetylsalicylic acid. Results: Measuring the tumour by ultrasonographic techniques, we observed a decrease of tumour volume of about 25%. Conclusion: These observations demonstrate that OA, GcMAF and NO can be properly combined and specifically delivered to advanced cancer patients with significant effects on immune system stimulation and tumour volume reduction avoiding harmful side-effects.

American Journal of Immunology 10 (1): 23-32, 2014

The first paper on the results in our Treatment Centre has been published.
The highlights of the results section include an average tumour reduction of 25% a week, and before and after ultrasonography scans of tumour shrinkage with measurements. Patient 3 is the most representative with a 27% reduction, and four other patients (not shown) with similar results. All 26 patients showed significant clinical improvements.

doi:10.3844/ajisp.2014.23.32 (http://www.thescipub.com/aji.toc)

Thi

Immuno Biotech presents GcMAF in the USA and Dubai

On the 1st February 2013 in simultaneous presentations at the 5th Immunotherapeutics Conference in San Diego, California, and 8,000 miles away at the PMTC International Cancer Conference at the University of Sharjah in the United Arab Emirates,  Immuno Biotech (gcmaf.eu) published its latest research abstract.

They included videos, taken through high powered microscopes in their laboratory, showing cancer cells being destroyed using GcMAF molecules, which they extract from the human immune system.

Lynda Thyer, one of Immuno Biotech’s biomedical scientists, had not been to the USA or presented to over 200 American scientists before. But she was congratulated by other scientists afterwards, and a number of scientists said her presentation would re-direct their work.

David Noakes, the CEO of Immuno Biotech, presented at the University of Sharjah, and was told afterwards his presentation was the most easily understood in the three days of the conference,  The University asked him to provide some GcMAF for use with their huge library of 2,000 cell lines, so that it can be tested with many more types of cancers in the laboratory. At the moment, GcMAF has human trials with many more types of cancer than it has in laboratory tests.

The University of Sharjah has facilities, funded, of course, by oil revenues, that Western Universities can only dream about. They are a top player with cancer and molecular research, attracting resident Professors from all over the world, and partners with the Gustave Roussy Cancer Institute in France, some of whose scientists said they would attend the GcMAF immunology Conference 2013 sponsored by Immuno Biotech.

David also made a third conference presentation, Immuno Biotechs “GcMAF in Autism” Research Paper co authored with Dr Jeffery Bradstreet at the International Dubai Autism Conference at the Zayed University Convention Centre, and has already been asked to supply GcMAF for autism trials there, adding to the 1500 results so far.

There are 59 research papers by 142 eminent scientists on GcMAF, and Immuno Biotech Ltd are immensely proud to be adding their first two research papers to the list, with plans for lab experiments and human trial results data for at least another 6 papers this year. The first of those is already finished, and has been accepted at the Immunotherapy and Immunomonitoring Conference Krakow, Poland, 22-24th April.

GcMAF is a vital part of our immune system; we don’t live long without it. Immuno Biotech extracts and isolates GcMAF in its laboratory, and has supplied 4,000 people through 300 doctors in 30 nations. Not bad for a tiny Guernsey company, particularly as HSSD tried to block them by making Guernsey the only nation in the world to ban GcMAF.

 Contact: Beate Keisa, Immuno Biotech Ltd.